Shopping Cart
- Remove All
- Your shopping cart is currently empty
AAK1-IN-5 is a potent and specific inhibitor of adaptor protein-2-associated kinase 1 (AAK1), characterized by its ability to penetrate the central nervous system and its oral bioavailability. It displays high selectivity, with an AAK1 inhibitory potency (IC 50) of 1.2 nM, a binding affinity (K i) of 0.05 nM, and an inhibitory potency against cellular AAK1 activity (cell IC 50) of 0.5 nM. AAK1-IN-5 holds promise for investigating neuropathic pain in scientific research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,140 | 8-10 weeks | |
50 mg | $2,785 | 8-10 weeks | |
100 mg | $3,520 | 8-10 weeks |
Description | AAK1-IN-5 is a potent and specific inhibitor of adaptor protein-2-associated kinase 1 (AAK1), characterized by its ability to penetrate the central nervous system and its oral bioavailability. It displays high selectivity, with an AAK1 inhibitory potency (IC 50) of 1.2 nM, a binding affinity (K i) of 0.05 nM, and an inhibitory potency against cellular AAK1 activity (cell IC 50) of 0.5 nM. AAK1-IN-5 holds promise for investigating neuropathic pain in scientific research [1]. |
In vitro | AAK1-IN-5 (compound 58), at a concentration of 0.5 μM administered over 0-10 minutes, demonstrates robust metabolic stability, exhibiting half-life durations exceeding 120 minutes in both human and mouse liver microsomes. In rat, cynomolgus monkey, and dog liver microsomes, its half-lives are recorded at 76.0, 17.6, and 26.0 minutes, respectively [1]. |
In vivo | AAK1-IN-5 (compound 58) effectively reduces hyperalgesia in male Sprague-Dawley rats with chronic constriction injury (CCI) at dosages of 1 and 3 mg/kg. Administered orally within a 0-5.5 hour timeframe, this compound significantly alleviates pain symptoms associated with CCI, supporting its therapeutic potential in similar conditions [1]. |
Molecular Weight | 385.4 |
Formula | C19H23F4N3O |
Cas No. | 1815613-44-5 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.